Home / Transcripts / Perrigo Company plc (PRGO) · February 26, 2026

Perrigo Company plc (PRGO) Earnings Call Transcript

February 26, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 46 min

Earnings Call Speaker Segments

Bradley Joseph executive
#1

Good day, everyone, and thanks for tuning in, whether it's morning or afternoon where you are. You're listening to Perrigo's call to discuss how we performed in Q4 and across all of 2025. The press release that went out earlier today, plus the slide deck we'll walk through during this discussion, can both be accessed on perrigo.com in the investor section. Joining us are Patrick Lockwood-Taylor, Perrigo's President and Chief Executive Officer, and Eduardo Bezerra, our Chief Financial Officer. Please keep in mind that some of what we say today will consist of forward-looking statements. Those statements come with significant risks and uncertainties, and you can find the specifics on the slides. We'll also be talking about adjusted financial measures, which fall into the non-GAAP category. You'll find more information, including reconciliations between all non-GAAP and GAAP financial measures we've presented, in the appendix of the earnings presentation. One more note: Patrick will only be speaking about non-GAAP financial measures. Now, here's the agenda. We have a number of topics to go through today. Patrick will start with an overview of the market, then summarize how we did in the fourth quarter and across all of 2025. After that, he'll discuss the progress we keep making on the Three-S plan and the shift to our new reporting segments, which kicks off in the first quarter of 2026. To wrap up, he will take you through what we expect for 2026, and then Eduardo will discuss our 2025 segment results, the balance sheet and how we're allocating capital, the program we have underway to improve operations, and finish with more specifics on the 2026 outlook. At this point, I'll hand things over to Patrick.

Patrick Lockwood-Taylor executive
#2

Thanks, Brad. Good morning, good afternoon, and I appreciate you all being on today's call. For Perrigo, 2025 brought significant advancement; we kept reshaping this company into a consumer health leader of world-class standing. That effort's outcomes are showing up more and more clearly in the market. Consumers and customers alike are choosing us. Evidence of this momentum appears in the robust share gains and the additional business we locked in with major retailers. Such wins demonstrate plainly that our strategy has taken hold and is producing results. Even with a soft market backdrop, we posted EPS matching our updated guidance, a healthy gain over the previous year. Considerable headway was made under our Three-S plan — simplify, streamline, and strengthen — even while infant formula kept confronting structural difficulties that hit both our financials and our outlook. Our 2026 outlook captures how the market actually stands today plus the effort needed to counter headwinds as we begin the year, which in our view are short-lived. Conditions should get better during the second half, we believe. Our confidence stays high that we can extend our progress and put Perrigo on a path toward long-term growth and value creation. Although the U.S. OTC market faced pressure, we picked up meaningful share in most categories where we compete. Crucially, those gains sped up as the year went on, turning around multiple years of losses. With consumers shifting toward store brands, we deepened retailer relationships, capturing more than $100 million from new distribution and competitive takeaways along with better in-store execution. That matters a great deal. It points to the fundamental strength of our business and shows we are winning back consumers and customers alike; the same favorable momentum is evident in Europe. Our main brands are picking up share despite a soft market backdrop, and our brand building, innovation, and go-to-market work is producing better marketplace results. Share increases on display in both regions confirm our strategy is delivering. We stay dedicated to bringing essential self-care within reach for everyone, drawing on over 250 molecules and formulations spanning every price point and value tier. That reflects the strength of our scale, which stands at approximately 10 times our closest competitors. Now to our financial results for the full quarter and full year 2025. As laid out in this morning's press release, we are presenting results through two lenses, all-in and CORE Perrigo. All-in captures our historical operations, whereas CORE Perrigo captures our go-forward business, leaving out infant formula and announced divestitures, chiefly the dermacosmetics business. To give better visibility into underlying performance, I will walk through results for all-in and CORE Perrigo; across the full year, despite soft market conditions weighing on consumption and net sales, we achieved strong operating income and EPS growth via operational rigor and disciplined cost management. Our all-in business increased operating income by 2% and EPS by 7%, ending at $2.75, exactly matching our updated guidance. CORE Perrigo operating income rose 7%, with CORE EPS climbing 14%. During quarter four, softness in the market kept dragging on what we delivered. Even though we picked up considerable share, CORE organic net sales fell 2% for the period, while CORE operating income dropped $4 million, or 2%, which left CORE EPS at $0.76 — down $0.02. What matters is that 2025 brought meaningful movement on our Three-S plan. To start, we got our store brand business back on stable footing, and you can see that in the share and distribution gains we posted. We likewise steadied supply and infant formula, bringing service levels back above 90%, even while demand recovery lost pace and rivalry heated up. Next, we simplified how the business runs, sharpening the portfolio through moves like the announced divestiture of the dermacosmetics business, which should wrap up during quarter two of this year, subject to final antitrust clearance, while we keep evaluating what role infant formula and oral care should play; on top of that, we carried out large efficiency programs, among them Project Energize and Supply Chain Reinvention, delivering $320 million in total benefits that lifted operating income and EPS. That same cost rigor carries into 2026, and Eduardo will walk through the details soon. Finally, we bolstered both our portfolio and our capabilities. Our main brands won share, and the value of our innovation pipeline came in at three times what it was a year earlier. We went deeper with retail partners by adding next-level demand generation capabilities; now that our new category model is in place and the executive team is fully assembled, we feel confident about our ability to drive end-to-end enterprise performance and keep carrying out our Three-S plan. Starting with the results we report for quarter one of 2026, we'll roll out new reporting segments: Self Care, Specialty Care, and infant formula. oral care, dermacosmetics, and other smaller distribution brands will sit within other. This fresh segmentation fits our global operating model and brings greater transparency to our categories. It also gives a clean picture of CORE Perrigo, the business that will fuel what comes next for us. Now to our 2026 outlook, which captures tough market conditions and the steps we need to take against temporary headwinds. As I noted, we anticipate OTC market consumption staying negative through the first half of 2026, since consumption so far in 2026 has softened further in the markets where we compete, partly because the cold season has been slow relative to a year ago. Dollar sales across the U.S. OTC market have fallen 5.1% over the past 13 weeks compared with a year earlier, versus a 4.3% decrease in quarter four and a 1.2% decrease across the whole of 2025. With consumption this slow, retailers are right-sizing their inventory to match current demand as well. That will show up most clearly in our quarter one results, given this figure and how steep the challenges are. Still, even against these sluggish market conditions, we expect to gain share faster than the market. Picking up where 2025 left off, our 2026 performance will come from consumer-centric innovation, stronger demand generation alongside top customers, targeted and opportunistic geographic expansion for our priority brands, and further distribution gains. We also expect there to be temporary yet meaningful pressure from plant under absorption because of reduced sales volumes in 2025 across both OTC and infant formula. The result is an unfavorable EPS effect for all in Perrigo in 2026 of roughly $0.60; for CORE Perrigo, organic net sales growth in 2026 is anticipated to fall between -3.5% and +0.5% versus 2025, while core EPS should land in the range of $2.25-$2.55. We see 2026 as a transition year while we navigate near-term headwinds along with the effects of temporary under absorption and market softness. Our confidence remains strong that our differentiated strategy, the stronger consumer base we built in 2025, and a more focused portfolio will put us in position for healthier top-line growth as conditions normalize. I'd also like to mention that we are finishing a growth algorithm for CORE Perrigo, and the early indicators are encouraging across growth, cash flow, and margin expansion. We look forward to sharing more on this later in the year; in closing, our focus for 2026 is clear: grow share in our key brands and deliver our innovation pipeline, continue driving U.S. store brand demand generation in partnership with retailers, deliver operational and cost-saving programs, continue our portfolio assessment efforts, and drive our category model and performance culture; we made clear progress winning with consumers and customers in 2025, we are excited about the possibilities ahead. We believe we are very well positioned to create long-term value. With that, I'll turn it over to Eduardo.

Eduardo Bezerra executive
#3

Thanks, Patrick. I'm glad everyone could be with us today. Before we dig into the specifics of our financials, I'd like to point out that our 2025 GAAP results contain non-cash accounting effects, among them a goodwill impairment charge totaling $1.3 billion. Impairment is a persistent matter that ties together the historic acquisition costs of businesses bought over time and the realities of the current stock price. In some cases, businesses acquired in the past have not delivered what was initially expected at the time of purchase. Management now has to confront those realities and plan for what comes next; this impairment has no bearing on our strategy, our cash flows, or our capacity to execute. Turning to the first quarter, we need to move goodwill from our existing reporting units to our new ones, which Patrick highlighted... Although the aggregate fair and carrying values remain the same as of December 31st, 2025, redistributing goodwill among our new reporting units could produce a different result, with surpluses in many and shortages in a few. Consequently, the company might record further non-cash goodwill impairment charges reaching as much as $350 million during the first quarter of 2026. Unlike impairment, which mirrors historical business performance, our choice to put business under strategic review is a response to external events, shaped by growth options and priorities for Perrigo going forward. On to our results. Like we pointed out, we're rolling out a fresh idea called CORE Perrigo results—or just core for short—that strips out infant formula along with divestitures we've already announced, primarily the dermacosmetics operation. Going forward, unless I say otherwise, everything I discuss will reflect adjusted non-GAAP figures. Turning to how each of our business units performed, let's start with CSCI. Core organic net sales for the full year dipped 0.2%, as gains from new products, market share improvements across the majority of our key brands, and better availability of pain and sleep aid offerings were outweighed by softer consumption. In the fourth quarter, core organic net sales fell to 1.4% compared with a year earlier. This decline stemmed from ongoing weakness in consumer demand within the OTC category, plus a cough and cold season that came in softer than the previous year's. For the full year, core operating income increased 11.6%, since cost savings generated by Project Energize, together with reduced variable expenses, outweighed the negative effects of gross profit flow-through. Core operating income for the fourth quarter was up 10.3%, helped by favorable foreign currency. For both the fourth quarter and the full year, every figure for net sales growth and operating income growth reflected the impact of divestment. Turning to CSCA now: for the full year, core organic net sales climbed to 3%. The drivers were reduced contract manufacturing revenue, weaker consumption in the category, and the stocking benefit from last year's Opill launch, with share gains providing a partial offset. In the quarter, core organic net sales slipped to 2.4%, again stemming from contract manufacturing and OTC category consumption, partly offset by share gains. For both the quarter and the full year, all-in net sales reflected infant formula declines of approximately 25% and 10%, in that order, since store brand growth was outweighed by reduced contract manufacturing and less distribution of the Good Start brand. CORE operating income for the full year and the fourth quarter decreased to 2.4% and 6.2%, respectively. In both periods, the decline came from reduced net sales volumes and price investment, though Project Energize savings and decreased variable operating expenses provided a partial offset. During the fourth quarter, all-in operating income was down $29 million, which included a $21 million negative effect from infant formula. Now turning to cash. As we exited 2025, the balance sheet held $532 million in cash, while fourth quarter operating cash flow came to $175 million, lifting our full-year total to $239 million. We closed out 2025 at a net leverage ratio of 4 times, a bit higher than our revised guidance, because of currency translation on gross debt along with smaller cash balances at year-end. Our capital allocation priorities remain exactly the same. We're focused on growing the business, reducing total debt and net leverage, and returning value to shareholders through dividends. Remember, we expect the dermacosmetics proceeds to assist in paying down debt in the second quarter. As we've stressed, starting with the earnings report for the first quarter of 2026, our segment reporting will match up with our commercial operating model and vision. To aid comparability, we'll recast some historical financial results under the new reporting segments, and we anticipate furnishing that on an 8-K in April. This shift in reporting segments won't impact the company's historical consolidated financial position, results of operations or cash flows. Given the outside forces we expect to face in 2026, we'll remain strict when it comes to controlling what we spend. A fresh two-year operational enhancement program is being launched to drive even greater productivity, make our operations more efficient, and sharpen our competitive edge; the aim is to reshape how we're organized so we can move faster, decide more quickly, and get more out of technology. Through this work, we expect to shrink our workforce worldwide by about 7%, and we'll additionally pursue cuts to operational costs, mostly in our supply chain and distribution network. Those steps ought to deliver yearly pre-tax savings between $80 million and $100 million, and roughly 80% of that should show up in 2026. We anticipate that roughly $80 million to $90 million will be needed in total to realize those savings. Now, a bit more color on what we're projecting for 2026. For CORE Perrigo, we're looking at organic net sales growth ranging from negative 3.5% to positive 0.5% compared with last year. We expect Core gross margin to land somewhere in the 39% to 40% range, and Core operating margin should come in between 15% and 16%. Inside CORE Perrigo, the elevated costs stemming from temporary OTC plans running below absorption should fade away during the coming 12 months, though how quickly things get back to normal will hinge on the timing and the levels of both sales and production volumes. Those cost pressures, along with increased advertising promotion spending and the reset of variable incentive plans, are going to be largely countered using two levers. To start, we have gains coming from the operational enhancement program we recently launched. On top of that, there are savings we're targeting—mostly from procurement efficiencies—partly because we now expect to produce lower volumes, plus we're pushing back some projects that aren't essential to what we've set as our 2026 strategic objectives. Turning to guidance for the whole company, this includes infant formula and assumes the dermacosmetics business sale closed during Q2 of this year. We expect all-in net sales growth of -5.5% to -1.5%. Gross margin should come in at 36.5%-37.5%, operating margin at 12.5% to 13.5%, and EPS between $2 and $2.30. Now let's discuss operating cash flow. With our Three-S plan moving ahead, there are short-term cash outlays we're taking on to boost productivity, make operations more efficient, and strengthen our risk profile — and we're doing that without losing sight of our goal to bring net leverage down. Turning to 2026, we expect operating cash flow conversion to stay around the mid-60% mark, and net leverage should end the year about even with, or slightly ahead of, where it lands in 2025. Because we're providing guidance for both all-in and CORE Perrigo to make side-by-side comparisons simpler, the 2025 actuals for each have been included in the appendix of this presentation. Now I'd like to quickly go through the 2026 EPS bridge. After removing infant formula and divestitures, our 2025 CORE baseline comes to $2.52. We expect the bulk of those other absorption costs, along with the advertising, promotion, and incentive investments that are returning to normal levels, to be canceled out by how the base business performs and by the savings we're getting from cost actions. Add in the net year-over-year swing from interest, taxes, and share count and effects, and that gets us to a CORE EPS range of $2.25-$2.55. When you fold everything in, the EPS range comes to $2.00-$2.30, which reflects what we anticipate from infant formula and divestiture. When you look at how CORE EPS is phased, the first half lands at roughly 30% to 35%, and the second half at 65% to 70%. That's a bit higher than what we normally see. It tracks with when we expect net sales to come in, and that includes the effect of a soft cough and cold season this year compared with last year, plus how our savings program is progressing and the impact of under absorption. To wrap up, we remain disciplined, realistic, and focused on what's within our control. The strategic moves we're making under our Three-S plan are making our foundation stronger for creating long-term value. We have confidence that CORE Perrigo can produce steady growth, margins that hold up, and dependable cash generation. The actions we're implementing at present are going to keep making our consumer health business stronger, so we can deliver results for consumers, customers, and shareholders. I'll hand things back over to Brad now. Brad?

Bradley Joseph executive
#4

Thanks, Eduardo. Operator, will you please open the line for questions?

Keith Devas executive
#5

Morning, and thanks for asking. There's quite a bit to cover, so I'll aim to be concise, though perhaps I should start with your 2026 outlook. I believe you brought up certain pressures during the first half, regarding cough, cold, and general consumption too, and you anticipate some improvement in the second half. Could you give a bit more detail or background on what's behind that second-half pickup, and then perhaps over the longer term, what's required for these categories, especially in OTC, in both the U.S. and international markets, to return them to stability and then ideally to growth?

Patrick Lockwood-Taylor executive
#6

Morning, Keith, and thanks for raising that. Obviously, a great deal of analysis has gone into this on our side, and many of our rivals have done the same. There are a few pieces to the answer. The first piece is: what is behind the decline? In our view, the vast majority of it is transitory in nature. Within certain subcategories, there has been a long-term reduction at the household level, though those represent only a modest slice of our total business. What does transitory mean here? Some trade down occurred; we observed consumers moving down into smaller units. We observed rollbacks from national brands, and the largest factor is that price increases did not reach the magnitude we have seen historically. That pulled a lot of value out of the market for a time, and we should treat that as roughly 90% of the cause. We begin to close the gap on those effects late in quarter two and progressively more through the second half. The consequence of that is simply normalization. Unless further value erosion appears relative to that base, by definition it settles. That is the effect we observe, increasingly in the second half. To get into the specifics of what builds our confidence: one, we expect share growth to continue. Two, we expect store brand OTC share growth to continue. Next, roughly 60% of the value from our innovation sits in the back half of this year. Roughly 65% of our opportunistic geographic expansion sits in the back half of this year. On our competitive takeaway — that is, our distribution gains — over half sits in the second half. This work you have heard us describe, this demand generation, which drives key retailers' store brand category along with their share of it and our share of that, nearly two-thirds of it lands in the back half of this year too. Putting all those factors together, we arrive at a more favorable outlook for the second half.

Keith Devas executive
#7

Understood — that's a big help. Possibly, to build on that, an update on where liquidity and leverage stand would be useful. You're launching a fresh restructuring effort, and that brings certain cash charges. Regarding how the business units look overall, it seems there's a bit of pressure, certainly through the first half. When you consider the guidance and holding net leverage unchanged versus last year, do you believe that leaves sufficient room to put money back into the business the right way, so you can achieve some of the shifts you're aiming for? Then there are your other obligations, like the dividend, and taking everything into account, hearing how you see liquidity and leverage would really help.

Eduardo Bezerra executive
#8

Thanks, Keith. On how we deploy capital, nothing has changed in terms of priorities, correct? We'll keep putting money into the business, right, by funding innovation and technology so we can keep accelerating alongside the new enhancement program we've announced; we remain focused on bringing leverage down, right? We anticipate the dermacosmetics divestiture will close in the early part of the second quarter, and those proceeds, as we said earlier, are going to be directed at cutting our debt, right? We'll also keep giving value back to shareholders via dividends, right? The dividend was kept where it was, and we keep evaluating it the way we always have. What matters, I think, is that we view 2026 as a transitional year, right? It's crucial to point out, you know, that we're seeing a big hit from under absorption — we touched on this a bit during the call — roughly $0.60, and a substantial chunk of that ought to come back in 2027. On top of that, these operational enhancement programs should hold up over time. Even though, let's say, from a free cash flow perspective, this is a tough year, you know, we think that's transitional and that conditions ought to get better as we move into 2027.

Keith Devas executive
#9

Thank you. I'll pass it on.

Eduardo Bezerra executive
#10

Thanks, Keith.

Executive executive
#11

Hello, Ethan here, filling in for Chris. We appreciate you answering our questions. Perhaps to begin, there was plenty of useful detail about the OTC business today. I was hoping to hear how you view margins bouncing back in that area, and whether that recovery will begin at some point during the back half of this year, or whether it's further out, in 2027 and beyond.

Eduardo Bezerra executive
#12

Okay, thanks for asking that. Let me offer a few thoughts, alright? We're looking at yet another absorption effect, you know, that's going to weigh on our margins during 2026, correct? That's among the main drivers behind why we're advocating for the operational enhancement program, right, the one we're putting into place this year. Still, our view is that this is temporary by nature, and it mostly captures, you know, the fallout from something that occurred during last year's second half. Even with the considerable share gain we've achieved in the U.S. OTC store brand business, plus our key brands internationally, we continued to hold substantial inventory. Naturally, the expense tied to that inventory has gone up, and we anticipate that temporary effect carrying into 2026. As I said, this ought to be temporary by nature. Once we see the market normalize further in the latter half of the year and on into 2027, that ought to fade away, and we ought to witness better margins in OTC moving forward.

Executive executive
#13

That's really useful. Perhaps I could ask just one more thing: when it comes to the infant formula business, how do you view the route toward getting operations and margins back to normal down the line, and what various steps can you take? On a wider level, regarding the strategic review, how are you weighing the various possibilities on the table, what a sale of some kind might look like, and should that not be an option, what alternatives could you pursue there? Thanks for fielding our questions.

Eduardo Bezerra executive
#14

All right. Yes. The review of our infant formula business is still underway, correct? We've got advisors helping us evaluate every option that's on the table, right? Is there a way to make our operations more efficient, along with possible partnerships and/or possible divestitures, right? You know, it's premature to say much about how far along that effort has gotten, because, you know, a great deal still has to be finished right now, and we'll share additional information on upcoming calls as things move forward.

Susan Anderson analyst
#15

Hello, and good morning. I appreciate you answering my question. I'm interested — when I look at those main sales segments, which ones would you say are experiencing the steepest declines, the ones pushing that outlook toward the bottom of the range for the current year? And then, which segments are performing above those? Thank you.

Patrick Lockwood-Taylor executive
#16

Sure thing, Susan, I appreciate that. Without having the figures right here with me, the categories leaning more toward prevention generally are faring better. VMS, certain subcategories within digestive wellness. The ones faring worse over a very near-term window, as you're aware, are cough, cold, and specific subsegments of pain. Primarily pill dosing is where we observe systemic household decline. That represents a modest portion of what we do, yet other areas of pain, especially topical creams, actually are doing quite well. Allergy, curiously enough, is also doing well in the early portion of this year. As we attempt to chart the rebound of each of those subsegments, we observe growth gaining strength in certain prevention categories. Allergy and cough, cold, clearly tied to seasons, but with rather weak seasons, we view quite favorably. We anticipate an average season, which it follows, is better than 25. Nothing we see is going to alter pain pill household penetration data. That is a very minor impact for us across the coming three years.

Susan Anderson analyst
#17

All right, that's quite useful. So as a quick follow-up regarding how we're allocating capital, I suppose, are you all at ease with where the dividend stands? Does that remain a priority? And then, I suppose, given the de-leveraging plans and the Derma proceeds, what are your longer-term leverage targets too? Thanks.

Patrick Lockwood-Taylor executive
#18

Appreciate that. I'll start, and then Eduardo, since this matters a lot and we both ought to weigh in. When it comes to capital allocation, our priorities haven't shifted — they're plain. We put money into the business, bring leverage down, and give value back to shareholders via dividends. As you're aware, we kept our dividends steady. We'll keep evaluating how we allocate capital based on what serves the business best and what produces the strongest sustainable return for shareholders.

Eduardo Bezerra executive
#19

Adding to what was said, regarding leverage — correct? As we pointed out, for 2026 we anticipate it will match 2025 or come in somewhat stronger. The primary reason is the one-time effects we see hitting our adjusted EBITDA across the business. Looking ahead, you know, we had earlier projected falling under 3 times in 2027, yet given these temporary market conditions, we now expect to reach that mark within the coming 2 to 3 years, once the new operational enhancement program wraps up, our strategic reviews covering both infant formula and oral care move forward, and consumption rebounds over time. Pinpointing the timing more exactly will hinge on each of these elements, Susan.

Susan Anderson analyst
#20

All right, wonderful. Perhaps I could just tack on one additional point regarding the infant nutrition segment. It seems to me that it's now a drag on earnings. I'm curious whether it ever returned to positive earnings and then subsequently went negative. And if you ultimately decide to retain it, what would be required to make it accretive to earnings once again? Thank you.

Eduardo Bezerra executive
#21

Sure, as I said earlier. The strategic review is still ongoing, correct? We are evaluating every option that's on the table, and naturally, we will determine which one delivers the best outcome for both the PNL and the cash flow. That's a key consideration, and we've been pointing out that infant formula has been a cash drain across multiple years. We're examining the full picture to identify what will serve shareholders best on both of those fronts, right? Since ultimately, we must remain dedicated to enhancing our cash flow generation moving forward.

Patrick Lockwood-Taylor executive
#22

Sure, I’ll add a little more from the commercial side. We anticipate that our share will keep expanding. I realize the figures you’re looking at cover the entire market, WIC included; since we don’t take part in WIC, we clearly examine it without WIC. In that review, we’re seeing solid growth for store brands, and we’re confident that as retailers reset shelves later in the year, that will work in our favor, since we have innovation coming and launches aimed at some of the foreign brands we’re observing in the U.S. That should help us; in fact, for infant formula this year we expect revenue growth in the low to mid single digit range. That lets us work through this lower margin inventory, which has been a major item in our EPS guidance. By doing so, gross profit begins moving back toward 24 to 25 levels; that’s how this model should play out this year from a commercial standpoint. As Eduardo said, there’s no question we need to examine plant optimization, align capacity with long-term volume, and optimize cost and cash in line with that. If we take that path, those are meaningful opportunities for margin and cash flow expansion.

Susan Anderson analyst
#23

All right, that's excellent. I truly appreciate it. That's very useful. Best of luck for the remainder of the year.

Patrick Lockwood-Taylor executive
#24

Thanks.

Daniel Biolsi analyst
#25

Thanks. Morning, everyone. To build on that previous question, could you tell us what amount of working capital—whether an average figure or any detail you're able to provide—typically goes along with the infant formula business?

Eduardo Bezerra executive
#26

The reason this matters comes down to how much stock we accumulated during the previous year, based on an expectation of a major share gain in the back half of the year. Because of the situation we've already looked at and discussed before — more government involvement plus a steady flow of imported goods entering the country at a substantial rate — we weren't able to win back share in the manner we'd intended and described at Investor Day last year, correct? That left us sitting on larger inventories, correct? As of the close of 2025, and, as Patrick noted, this net sales plan in the low to mid-single digit range ought to assist with drawing down that inventory over the course of this year, correct? And that ought to move working capital back toward more typical levels compared with what we dealt with previously.

Daniel Biolsi analyst
#27

All right, thanks. It's good to see gross margins holding nearly steady once you set aside the infant formula business. During your prepared remarks, you brought up a pricing investment in CSCI. So what were the results? What sort of reaction did that pricing investment in CSCI generate?

Patrick Lockwood-Taylor executive
#28

Right, so this is something that happens annually. We're competing in a wide variety of molecules. You've got capacity that's out there in the U.S., or you can get it from manufacturers abroad that have lower costs. And simply put — and honestly, this comes down to suppliers being swapped out — that puts pressure on margin. For a couple of decades now, that's simply been the situation with certain molecules of ours, all right? It's basically a yearly expense you have to pay just to be in the game; what we now have is a systematic program that tackles it — productivity, mix, innovation, moving into adjacencies that are more profitable, and naturally, pushing additional volume through our farms. Each point of utilization translates to roughly $10 million for us. We've gotten significantly better at master planning those activities, simply acknowledging that cost and commoditization. That's what lets us maintain or grow gross profit from one year to the next, but it's a key piece of where we compete, all right? Looking back, we likely didn't place enough value on that, which brought risk into our PNL. My sense is we now have far greater visibility and control over that as we move forward. And as we boost the salience of our branded business by putting more emphasis on brand, by putting more emphasis on branded growth and share growth, that clearly has a strongly favorable effect not only on GP, but on OI margin too. Clearly, branded items tend to run higher on both of those. Essentially, it comes down to doing a far better job of managing the gross profit profile of our store brand business, while simultaneously driving the salience of our branded business. That's what enables us to safeguard and boost both OI and GP.

Daniel Biolsi analyst
#29

Thanks.

Patrick Lockwood-Taylor executive
#30

Yes, many thanks, I appreciate you being with us today and I appreciate those excellent questions. The market we're dealing with right now is a difficult one; what falls under our control must be led by us, and what doesn't fall under our control must be handled with excellence. The fundamentals of this business are being repaired by us, and our belief is that we're putting this business in position for growth of high quality. After declining for many years, we're now growing share on a consistent basis. Together with our key retailers, we're making the category bigger. Within the U.S., store brand OTC is gaining share, and of that expanding category, we're taking a growing piece. Our financial structure is being improved by us. Over the last two and a half years, OI margin is up 230 basis points, net leverage has fallen from 5.5 to 4, and further deleveraging will continue. More effective, more consistent, and more compliant is what our operations have become. In 25, we underwent 30 + inspections, and there were no critical or major observations, plus no recalls. Quality assurance is where we set the standard. Our leadership team and our senior management are in place. Experienced and world-class they are, they're driven by performance, and they're competitive on cost. An expandable growth model that will drive TSR is now something we have in place. A differentiated and clear purpose is ours. Essential everyday self-care for everyone is why we exist. Our portfolio has been streamlined, and we play in markets and increasingly in categories where the right to win belongs to us and where profit size is attractive. The core strengths of this company drive these categories and are reinforced by them. More molecules are ours. More price points are covered by us. In the end, more consumers are reached because of that. Even deeper and more strategic customer partnerships are being developed by us. Through scaled, high-quality, regionalized supply chains is how we win. Extensive regulatory interface is something we have, and for these categories going forward, that lets us shape the regulatory environment. Geographic and category opportunities where these strengths can be operationalized in order to drive advantage are now what we're set to pursue. Keep in mind, only 10% of the world's consumers are served by us today. A tremendous growth runway is what this gives us. Businesses where our growth model can't be leveraged have been divested by us, e.g., dermacosmetics, rare diseases, et cetera. To wrap up, our confidence in our model and the path forward keeps increasing. A meaningful growth year is what 2027 is shaping up to be. Once more, thanks for being with us.

Operator operator
#31

Thank you. That brings us to the end of the conference call for today, ladies and gentlemen. I appreciate everyone for participating. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Perrigo Company plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Perrigo Company plc earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.